By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity. - 2Fire Allegedly Triggered by Wedding Cake Sparkler Causes Venue to Go Up in Flames, Leaving Groom with Second-Degree Burns
- 3Rick Steves' Favorite Time To Visit Spain Has Lower Prices And Fewer Crowds
- 43 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- 5‘Ukrainian housewives’ and Skyranger delays – German defense poster child Rheinmetall is in hot water
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- Hungary's 'water guardian' farmers fight back against desertification
- The Most Enrapturing Authentic Milestones to Visit
- The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs
- Carry Nature Inside with These Staggering Plant Decisions
- Vacuum Cleaners That Are Not difficult To Use For Home
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- NAFFIC and Aware to Launch First China-Europe Digital Product Passport
